May 29, 2020

Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

Open Forum Infectious Diseases
Thomas LodiseJennifer Schranz

Abstract

Time to clinical response, a proxy for hospital "discharge readiness," was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical response (4 days) was observed in both treatment groups.

  • References
  • Citations1

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations1

Citations

Mentioned in this Paper

Double-Blind Method
Moxifloxacin
Hospitals
Pneumonia, Bacterial
Clinical Trials
Phase 3 Clinical Trials
Pneumonia
Evaluation
No Charge for Medical Care due to Enrollment in Research/Clinical Trial

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.